临床药师参与“毛细支气管炎”临床路径制定的方法及效果分析

The Way of Clinical Pharmacist Participating in Clinical Pathway Treating Capillary Bronchitis and Effect Analysis

目的探讨临床药师参与"毛细支气管炎"临床路径实施的方法和效果。方法临床药师参与临床路径制定后,回顾性分析我院临床路径实施前后第一诊断为"毛细支气管炎"患儿病历,比较临床路径实施前与临床路径实施后的患儿抗菌药物使用情况、住院费用,药品费用,住院天数,探讨临床药师参与临床路径的方法及效果。结果临床路径实施前后,患儿使用抗菌药物情况之间有统计学差异(P<0.01);患者住院总费用、药品费用和住院天数之间有统计学差异(P<0.01或P<0.05),临床路径实施后,患者的住院总费用、药品费用和住院天数都明显减少。结论临床药师参与临床路径制定,规范了患者用药,节约了住院费用和药品费用,缩短了住院天数,对节约治疗成本,切实减轻患者经济负担有重要的意义。

Objective To discuss the way and the effect of clinical pharmacist participating in clinical pathway treating capillary bronchitis. Method After formulating the way clinical pharmacist participating in clinical pathway, we analyzed the case histories with the first diagnosis of capillary bronchitis retrospectively, compared the using of antibacterial agents, hospitalization expenses, medicine expenses and in hospital days before and after clinical pathway, discussed the way and effect of clinical pharmacist participating in clinical pathway. Result The using of antibacterial agents had statistical difference （P＆lt;0.01）;the hospitalization expenses, medicine expenses and in hospital days had statistical difference （P＆lt;0.05 or P＆lt;0.01） before and after clinical pathway, After clinical pathway, the hospitalization expenses, medicine costs and in hospital days were reduced obviously. Conclusion The clinical pharmacist participating in clinical pathway formulating, can standardize drug use for patient, save the hospitalization expenses, medicine costs, short the days in hospital, it had important meaning in economizing the cost of treating, reducing the economic burden to patient.